TELO / Telomir Pharmaceuticals, Inc. - Documents déposés auprès de la SEC, rapport annuel, procuration

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2025 TELOMIR PHARMAC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 TELOMIR PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2025 TELOMIR PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41952 Telomir Pharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 TELOMIR PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 TELOMIR PHARMACEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2025 TELOMIR PHARMACEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Commiss

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Commiss

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Commiss

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Commiss

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Commissi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Commissi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Commissi

Other Events, Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Commissi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Commissi

Employment Agreement, dated May 15, 2025, between Telomir Pharmaceuticals, Inc. and Alan Weichselbaum.

Exhibit 10.1 May 15, 2025 Re: Employment Letter Agreement Dear Mr. Weichselbaum: Telomir Pharmaceuticals, Inc. (the “Company”) is pleased to offer you employment on the following terms. Subject to any pre-employment requirements, your employment will commence on May 19, 2025 (the “Start Date”) or such other date as you and the Company may agree. 1. Position and Responsibilities. Your title will be

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41952 Telomir Pharm

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Commissio

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Commis

Telomir Pharmaceuticals, Inc. 100 SE 2nd St, Suite 2000, #1009 Miami, Florida

Telomir Pharmaceuticals, Inc. 100 SE 2nd St, Suite 2000, #1009 Miami, Florida February 26, 2025 VIA EDGAR U.S. Securities & Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Telomir Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-284990 Ladies and Gentlemen: In accordance with Rule 461 of the Securities A

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Com

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Com

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Com

As filed with the Securities and Exchange Commission on February 14, 2025

As filed with the Securities and Exchange Commission on February 14, 2025 Registration No.

At The Market Offering Agreement, dated February 14, 2025, by and between Telomir Pharmaceuticals, Inc. and Rodman & Renshaw LLC.**

Exhibit 1.2 AT THE MARKET OFFERING AGREEMENT February 14, 2025 Rodman & Renshaw LLC 600 Lexington Avenue, 32nd Floor New York, NY 10022 Ladies and Gentlemen: Telomir Pharmaceuticals, Inc., a corporation organized under the laws of Florida (the “Company”), confirms its agreement (this “Agreement”) with Rodman & Renshaw LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used

Filing Fee Table.**

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Telomir Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-31361 Telomir Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 TELOMIR PHARMACE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Comm

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Commi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Com

Letter from Cherry Bekaert LLP dated December 20, 2024

Exhibit 16.1 December 20, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated December 20, 2024 of Telomir Pharmaceuticals, Inc. and are in agreement with the statements contained therein as it regards our firm. We have no basis to agree or disagree with any other statements of the registrant contained in It

Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 TELOMIR PHARMACE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Comm

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Comm

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Com

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41952 Telomir P

Promissory Note and Loan Agreement, dated September 24, 2024, between the and The Starwood Trust.

Exhibit 10.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE APPLICABLE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE PLEDGED, SOLD, ASSIGNED OR OTHERWISE TRANSFERRED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION UNDER SUCH LAWS OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENT. LENDER SHOULD BE A

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2024 (September 24, 2024) TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Com

Employment Agreement between the Company and Erez Aminov, dated August 12, 2024.

Exhibit 10.1 Employment Agreement This Employment Agreement (this “Agreement”) is made and entered into as of August 12, 2024 (the “Effective Date”), by and between Telomir Pharmaceuticals, Inc. (the “Company”) and Erez Aminov (“Employee”). In consideration of the mutual promises and covenants set forth herein, and other good and valuable consideration, the sufficiency of which is hereby acknowled

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41765 Telomir Pharma

Employment Agreement by and between the Company and Michelle Yanez, dated June 18, 2024 (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on June 24, 2024)

Exhibit Employment Agreement This Employment Agreement (this “Agreement”) is made and entered into as of [], 2024 (the “Effective Date”), by and between TELOMIR Pharmaceuticals, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41765 Telomir Pharm

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Commis

Company Presentation, dated April 15, 2024

Exhibit 99.1

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2024 (April 10, 2024) TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incor

Description of Securities

Exhibit 4.4 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 After giving effect to the filing of our Second Amended and Restated Articles of Incorporation and the 1-for-2.05 reverse stock split that we completed on December 11, 2023, the total number of shares of common stock our company is authorized to issue is presently 300,000,000 shares, no p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-31361 Telomir Pharmaceuticals, Inc.

Policy Relating to Recovery of Erroneously Awarded Compensation

Exhibit 97.1 TELOMIR PHARMACEUTICALS, INC. Compensation Recovery Policy 1. Purpose. The purpose of this Compensation Recovery Policy (this “Policy”) is to describe the circumstances under which Telomir Pharmaceuticals, Inc. (the “Company”) is required to recover certain compensation paid to certain employees. Any references in compensation plans, agreements, equity awards or other policies to the

Telomir Pharmaceuticals Announces Pricing of Initial Public Offering

Exhibit 99.1 Telomir Pharmaceuticals Announces Pricing of Initial Public Offering Baltimore, Maryland, February 8, 2024 — Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, is developing Telomir-1 as the first novel small molecule, to lengthen the DNA’s protective telomere caps in order to affect age reversal, t

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 001-41952 87-2606031 (State or Other Jurisdiction of Incorporation) (Comm

Representative’s Warrant, dated February 13, 2024.

Exhibit 4.1 Representative’s Warrant Agreement THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS

Underwriting Agreement, dated as of February 8, 2024, by and among the Company, Kingswood Investments, division of Kingswood Capital Partners, LLC and the other underwriters named therein.

Exhibit 1.1 UNDERWRITING AGREEMENT between TELOMIR PHARMACEUTICALS, INC. and KINGSWOOD INVESTMENTS, division of Kingswood Capital Partners, LLC, as Representative of the Several Underwriters UNDERWRITING AGREEMENT between TELOMIR PHARMACEUTICALS, INC. and KINGSWOOD INVESTMENTS, division of Kingswood Capital Partners, LLC, as Representative of the Several Underwriters New York, New York February 8,

Telomir Pharmaceuticals Announces Closing of Initial Public Offering

Exhibit 99.2 Telomir Pharmaceuticals Announces Closing of Initial Public Offering Baltimore, February 13, 2024 — Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to affect age re

1,000,000 Shares Common Stock

Filed Pursuant to Rule 424(b)(1) Registration No. 333-275534 PROSPECTUS 1,000,000 Shares Common Stock This is the initial public offering of 1,000,000 shares of common stock, no par value, of Telomir Pharmaceuticals, Inc. Prior to this offering, there has been no public market for shares of our common stock. The assumed initial public offering price is $7.00 per share. Our common stock has been ap

6,203,696 Shares Common Stock

Filed Pursuant to Rule 424(b)(4) Registration No. 333-275534 PROSPECTUS 6,203,696 Shares Common Stock This prospectus relates to up to 6,203,696 shares of common stock, no par value, of Telomir Pharmaceuticals, Inc., which consists of (i) 3,764,671 shares of common stock issued to the selling stockholders named in this prospectus, and (ii) 2,439,025 shares of common stock issuable upon the exercis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 TELOMIR PHARMACEUTICALS, INC. (Exact name of re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 TELOMIR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Florida 87-2606031 (State of Incorporation or Organization) (I.R.S. Employer Identification No.) 855 N Wolfe Str

Kingswood Investments, division of Kingswood Capital Partners, LLC 17 Battery Place, Suite 625 New York, New York 10004

Kingswood Investments, division of Kingswood Capital Partners, LLC 17 Battery Place, Suite 625 New York, New York 10004 February 6, 2024 VIA EDGAR U.

TELOMIR PHARMACEUTICALS, Inc. 900 West Platt Street, Suite 200 Tampa, Florida 33606 February 6, 2024

TELOMIR PHARMACEUTICALS, Inc. 900 West Platt Street, Suite 200 Tampa, Florida 33606 February 6, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Tara Harkins, Lynn Dicker, Jimmy McNamara, and Joe McCann Re: Telomir Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed November 14,

January 3, 2024

ATTORNEYS AT LAW 100 North Tampa Street, Suite 2700 Tampa, FL 33602-5810 P.O. Box 3391 Tampa, FL 33601-3391 813.229.2300 TEL 813.221.4210 FAX www.foley.com WRITER’S DIRECT LINE 813.225.4122 [email protected] January 3, 2024 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, DC 20549 Attention: Tara Harkins, Lynn Dicker, Ji

As filed with the Securities and Exchange Commission on January 3, 2024

As filed with the Securities and Exchange Commission on January 3, 2024 Registration No.

Form of Underwriting Agreement

Exhibit 1.1 UNDERWRITING AGREEMENT between TELOMIR PHARMACEUTICALS, INC. and KINGSWOOD INVESTMENTS, division of Kingswood Capital Partners, LLC, as Representative of the Several Underwriters UNDERWRITING AGREEMENT between TELOMIR PHARMACEUTICALS, INC. and KINGSWOOD INVESTMENTS, division of Kingswood Capital Partners, LLC, as Representative of the Several Underwriters New York, New York [●], 2023 K

Form of Representative’s Warrant

Exhibit 4.1 Form of Representative’s Warrant Agreement THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGH

As filed with the Securities and Exchange Commission on December 19, 2023

As filed with the Securities and Exchange Commission on December 19, 2023 Registration No.

Form of Common Stock Purchase Warrant, by and between the Company and certain investors from January 2023 through March 2023

Exhibit 4.3 THIS WARRANT AND THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE SEC

Amended and Restated Bylaws of Telomir Pharmaceuticals, Inc.

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF TELOMIR PHARMACEUTICALS, INC. (a Florida corporation) 1 Article 1 OFFICES Telomir Pharmaceuticals, Inc. (the “Corporation”) may have such principal and other business offices, either within or without the State of Florida, as the Board of Directors may designate or as the business of the Corporation may require from time to time. Article 2 SHAREHOLDERS Se

Second Amended and Restated Articles of Incorporation of Telomir Pharmaceuticals, Inc.

Exhibit 3.1 SECOND AMENDED AND RESTATED ARTICLES OF INCORPORATION OF TELOMIR PHARMACEUTICALS, INC. (Pursuant to Sections 607.1007 and 607.1003 of the Florida Business Corporation Act) Telomir Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the provisions of the Florida Business Corporation Act (the “FBCA”), DOES HEREBY CERTIFY: 1. That this Corporation is named T

December 14, 2023

ATTORNEYS AT LAW 100 North Tampa Street, Suite 2700 Tampa, FL 33602-5810 P.O. Box 3391 Tampa, FL 33601-3391 813.229.2300 TEL 813.221.4210 FAX www.foley.com WRITER’S DIRECT LINE 813.225.4122 [email protected] December 14, 2023 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, DC 20549 Attention: Tara Harkins, Lynn Dicker,

Code of Business Conduct and Ethics

Exhibit 14.1 TELOMIR PHARMACEUTICALS, INC. CODE OF ETHICS AND CONDUCT In accordance with the requirements of the Securities and Exchange Commission (the “SEC”) and the Initial Listing Standards of the Nasdaq Stock Exchange (“Nasdaq”), the Board of Directors (the “Board”) of Telomir Pharmaceuticals, Inc. (the “Company”) has adopted this Code of Ethics and Conduct (the “Code”) to encourage: ● Honest

Audit Committee Charter

Exhibit 99.1 TELOMIR PHARMACEUTICALS, INC. AUDIT COMMITTEE CHARTER The Board of Directors (the “Board”) of Telomir Pharmaceuticals, Inc. (the “Company”) has established a standing Audit Committee (the “Committee”) pursuant to Section 607.0825 of the Florida Business Corporation Act (“FBCA”) and for the purposes described in this charter of the Committee (the “Committee Charter”). I. Purpose of the

Agreement for Shared Lease Costs, dated April 1, 2023, between Telomir Pharmaceuticals, Inc., MIRALOGX LLC, and MIRA Pharmaceuticals, Inc.

Exhibit 10.9 AGREEMENT FOR SHARED LEASE COSTS This Agreement for Shared Lease Costs (the “Agreement”) is made, effective as of April 1, 2023 by and among MIRALOGX LLC. (“ MIRALOGX”), MIRA Pharmaceuticals, Inc. (“MIRA” ) and Telomir Pharmaceuticals, Inc. (“Telomir”), all with a mailing address of 900 West Platt Street, Suite 200, Tampa, Florida 33606. RECITALS WHEREAS, MIRALOGX has entered into an

Debt Conversion Agreement, dated November 30, 2023, between Telomir Pharmaceuticals, Inc., and the Bay Shore Trust.

Exhibit 10.11 DEBT Conversion Agreement This Debt Conversion Agreement (this “Agreement”) is entered into effective as of November 30, 2023 (the “Effective Date”) by and between the Bay Shore Trust (“Bay Shore Trust”), and Telomir Pharmaceuticals, Inc., a Florida corporation with its principal executive office located at 855 N Wolfe Street, Suite 601, Baltimore, Maryland 21205 (“Telomir”); Bay Sho

Nominating and Corporate Governance Committee Charter

Exhibit 99.2 telomir PHARMACEUTICALS, INC. NOMINATING & GOVERNANCE COMMITTEE CHARTER The Board of Directors (the “Board”) of Telomir Pharmaceuticals, Inc. (the “Company”) has established a standing Nominating & Governance Committee (the “Committee”) pursuant to Section 607.0825 of the Florida Business Corporation Act (“FBCA”) and for the purposes described in this charter of the Committee (the “Co

Promissory Note and Loan Agreement, dated June 15, 2023, by and between Telomir Pharmaceuticals, Inc. and Bay Shore Trust

Exhibit 10.8 FLORIDA DOCUMENTARY STAMP TAX IN THE AMOUNT $2,450.00 HAS BEEN PAID OR WILL BE PAID DIRECTLY TO THE FLORIDA DEPARTMENT OF REVENUE. PROMISSORY NOTE AND LOAN AGREEMENT Tampa, FL $5,000,000 June 15, 2023 FOR VALUE RECEIVED AND IN CONSIDERATION OF THE LOAN, Telomir Pharmaceuticals, Inc., a Florida corporation (the “Borrower”), hereby promises to pay to the order of George Cappy, as Truste

Insider Trading Policy

Exhibit 99.5 TELOMIR PHARMACEUTICALS, INC. Insider Trading Policy This policy applies to all employees at every level of the Company and its subsidiaries, including the directors of the Company. Overview Given that the common stock of the Telomir Pharmaceuticals, Inc. (the “Company”) is traded on the Nasdaq Capital Market, there are certain important restrictions and limitations imposed on you und

Corporate Governance Guidelines

Exhibit 99.4 TELOMIR PHARMACEUTICALS, INC. CORPORATE GOVERNANCE GUIDELINES The Board of Directors (the “Board”) of Telomir Pharmaceuticals, Inc. (the “Company”) has adopted the following Corporate Governance Guidelines (the “Guidelines”) to assist the Board in the exercise of its responsibilities and to serve the interests of the Company and its stockholders. These Guidelines should be interpreted

Related Person Transaction Policy and Procedures

Exhibit 99.6 TELOMIR PHARMACEUTICALS, INC. Related Person Transaction Policy and Procedures I. POLICY Telomir Pharmaceuticals, Inc. (the “Company”) recognizes that related person transactions present a heightened risk of conflicts of interest (or the perception thereof) and therefore the Company has adopted this policy (this “Policy”) pursuant to which all Related Person Transactions (as defined b

Compensation Committee Charter

Exhibit 99.3 TELOMIR PHARMACEUTICALS, INC. COMPENSATION COMMITTEE CHARTER The Board of Directors (the “Board”) of Telomir Pharmaceuticals, Inc. (the “Company”) has established a standing Compensation Committee (the “Committee”) pursuant to Section 607.0825 of the Florida Business Corporation Act (“FBCA”) and for the purposes described in this charter of the Committee (the “Committee Charter”). I.

Form of Stock Option Award under 2023 Omnibus Incentive Plan

Exhibit 10.2 TELOMIR PHARMACEUTICALS, INC. 2023 OMNIBUS INCENTIVE PLAN STOCK OPTION AWARD [PARTICIPANTID] [FIRSTNAME] [LASTNAME] You have been granted an option (your “Option”) to purchase shares (“Shares”) of Common Stock of Telomir Pharmaceuticals, Inc. (the “Company”) under the Telomir Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan, as amended and restated (the “Plan”), effective as of the G

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) TELOMIR PHARMACEUTICALS, INC.

Form of Indemnification Agreement

Exhibit 10.3 INDEMNIFICATION AGREEMENT This Indemnification Agreement (the Indemnification Agreement”) is made and entered into as of [●], [●], by and between TELOMIR PHARMACEUTICALS, INC., a Florida corporation (the “Company”), and , an individual (“Indemnitee”). WHEREAS, it is essential to the Company to retain and attract qualified directors and officers; WHEREAS, Indemnitee is a director and/o

As filed with the Securities and Exchange Commission on December 14, 2023

As filed with the Securities and Exchange Commission on December 14, 2023 Registration No.

Common Stock Purchase Warrant, dated June 15, 2023, between Telomir Pharmaceuticals, Inc. and Bay Shore Trust

Exhibit 4.2 THIS WARRANT AND THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE SEC

2023 Omnibus Incentive Plan

Exhibit 10.1 TELOMIR PHARMACEUTICALS, INC. 2023 OMNIBUS INCENTIVE PLAN 1. Purposes and Effective Date. (a) Purposes. The Telomir Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan has two complementary purposes: (i) to attract and retain outstanding individuals to serve as officers, directors, employees, and consultants and (ii) to increase shareholder value. The Plan will provide participants ince

Debt Conversion Agreement, dated November 30, 2023, between Telomir Pharmaceuticals, Inc., and MIRALOGX LLC

Exhibit 10.10 DEBT Conversion Agreement This Debt Conversion Agreement (this “Agreement”) is entered into effective as of November 30, 2023 (the “Effective Date”) by and between MIRALOGX LLC, a Florida limited liability company with its principal executive office located at 900 West Platt Street, Suite 200, Tampa, Florida 33606 (“MIRALOGX”), and Telomir Pharmaceuticals, Inc., a Florida corporation

List of Subsidiaries of Registrant

Exhibit 21.1 List of Subsidiaries of Telomir Pharmaceuticals, Inc. Legal Name Jurisdiction None Not applicable

Amended and Restated Employment Agreement, dated December 11, 2023, between Telomir Pharmaceuticals, Inc. and Nathen Fuentes, CPA.

Exhibit 10.6 First Amended and Restated Employment Agreement This First Amended and Restated Employment Agreement (this “Agreement”) is made and entered into as of December 11, 2023 (the “Effective Date”), by and between TELOMIR Pharmaceuticals, Inc. (the “Company”) and Nathen Fuentes (“Employee”). This Agreement amends and restates, and supersedes in its entirety, that certain Employment Agreemen

Employment Agreement, dated September 21, 2023, between Telomir Pharmaceuticals, Inc. and Nathen Fuentes, CPA

Exhibit 10.6 Employment Agreement This Employment Agreement (this “Agreement”) is made and entered into as of September 21 , 2023 (the “Effective Date”), by and between TELOMIR Pharmaceuticals, Inc. (the “Company”) and Nathen Fuentes (“Employee”). In consideration of the mutual promises and covenants set forth herein, and other good and valuable consideration, the sufficiency of which is hereby ac

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) TELOMIR PHARMACEUTICALS, INC.

Employment Agreement, effective as of the date of the closing of the initial public offering, between Telomir Pharmaceuticals, Inc. and Dr. Christopher Chapman, Jr., MD

Exhibit 10.7 Employment Agreement This Employment Agreement (this “Agreement”) is made and entered into as of the beginning of the Initial Public Offering (the “Effective Date”), by and between TELOMIR Pharmaceuticals, Inc. (the “Company”) and Christopher Chapman, Jr., MD (“Employee”). In consideration of the mutual promises and covenants set forth herein, and other good and valuable consideration

As filed with the Securities and Exchange Commission on November 14, 2023

As filed with the Securities and Exchange Commission on November 14, 2023 Registration No.

Amendment No. 1 to Amended and Restated License Agreement, dated November 10, 2023, by and between Telomir Pharmaceuticals, Inc. and MIRALOGX LLC

Exhibit 10.5 AMENDMENT NO. 1 TO AMENDED & RESTATED EXCLUSIVE LICENSE AGREEMENT THIS AMENDMENT NO. 1 TO AMENDED & RESTATED EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), dated as of November [ ], 2023, amends that certain Amended and Restated Exclusive License Agreement, effective as of November 29, 2022 (the “License Agreement”), between MIRALOGX LLC, a Florida limited liability company (“Licenso

Amended and Restated License Agreement, dated August 11, 2023, by and between Telomir Pharmaceuticals, Inc. and MIRALOGX LLC

Exhibit 10.4 AMENDED & RESTATED EXCLUSIVE LICENSE AGREEMENT THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of August 11, 2023 and is retroactive to November 29, 2022 (the “Effective Date”), when the Exclusive License Agreement was first entered by and between MIRALOGX LLC, a Florida limited liability company located at 900 West Platt St., Suite 200, Tampa, FL 33606 (“Licens

November 13, 2023

ATTORNEYS AT LAW 100 North Tampa Street, Suite 2700 Tampa, FL 33602-5810 P.O. Box 3391 Tampa, FL 33601-3391 813.229.2300 TEL 813.221.4210 FAX www.foley.com WRITER’S DIRECT LINE 813.225.4122 [email protected] November 13, 2023 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, DC 20549 Attention: Tara Harkins, Lynn Dicker,

Draft No. 2 confidentially submitted to the Securities and Exchange Commission on October 16, 2023 This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly c

Draft No. 2 confidentially submitted to the Securities and Exchange Commission on October 16, 2023 This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE S

October 16, 2023

ATTORNEYS AT LAW 100 North Tampa Street, Suite 2700 Tampa, FL 33602-5810 P.O. Box 3391 Tampa, FL 33601-3391 813.229.2300 TEL 813.221.4210 FAX www.foley.com WRITER’S DIRECT LINE 813.225.4122 [email protected] October 16, 2023 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, DC 20549 Attention: Tara Harkins, Lynn Dicker, J

As confidentially submitted to the Securities and Exchange Commission on August 14, 2023 This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidentia

As confidentially submitted to the Securities and Exchange Commission on August 14, 2023 This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential.